DNA will be assessed by PCR and Southern blot analysis at 1, 7 and 13 days post each T cell 
infusion. HIV specific CTL generation will also be characterized at these times. Changes over time 
will be assessed. To describe the activity of the virus, the results of the HIV-1 Western blot, HIV-1 
p24 antigen on serum, and other tests listed in section 7E. Additional follow-up evaluations will be 
examined and compared over time for each individual patient and overall. 
The type and grade of toxicities noted during study will be tabulated. Clinically important changes 
from baseline in the laboratory variables will be summarized, all adverse events noted by the 
investigator will be tabulated and summarized according to the affected body system. 
The study will be stopped early and reevaluated if any two patients fail to engraft after BMT as 
determined using criteria listed in Table 2, or if any three patients develop neurologic, pulmonary, or 
hematopoietic toxicity requiring T cell ablation. If transferred HIV-specific T cells persist in vivo for 
less than 7 days in all of the first five patients treated, the study will be stopped and reevaluated. The 
study may also be stopped early if the initial five patients survive longer than twelve months and 
remain free of HIV-1 infection. 
10. References 
1. Barre-Sinoussi F, Chermann JC, Rey F, et al: Isolation of a T-lymphotropic retrovirus from a patient 
at risk for acquired immune deficiency syndrome (AIDS). Science 220:868, 1983. 
2. Popovic M, Sarngahadaran MG, Read E, et al: Detection, isolation and continuous production of 
cytopathic retroviruses (HTLVIII) from patients with AIDS and preAIDS. Science 224-497, 1984. 
3. Curran JW, Jaffe WH, Hardy AM, et al: Epidemiology of HIV infection and AIDS in the United 
States. Science 239:610, 1988. 
4. Levy J A: Mysteries of HIV: Challenges for therapy and prevention. Nature 333:519, 1988. 
5. Rothenberg R, Woelful BA, Stoneburner R, et al: Survival with the acquired immunodeficiency 
syndrome-experience with 5833 cases in New York City. N Engl J Med 317:1297, 1987. 
6. Lemp GJ, Payne SF, Neal D, et al: Survival trends for patients with AIDS. JAMA 263-402, 1990. 
7. Creagh-Kirk T, Doi P, Andrews E, et al: Survival experience among patients with AIDS receiving 
zidovudine. JAMA 260:3009, 1988. 
8. Volberding PA, Lagakos SW, Koch MA, et al: Zidovudine in asymptomatic human 
immunodeficiency virus infection: A controlled trial in persons with fewer than 500 CD4-positive 
cells per cubic millimeter. N Engl J Med 322:941, 1990. 
9. Larder BA, Darky G, Richmann DD: HIV with reduced sensitivity to zidovudine (AZT) isolated 
during prolonged therapy. Science 243:1731, 1989. 
10. Levine AM: Lymphoma in acquired immunodeficiency syndrome. Semin Oncol 17:104-112, 1990. 
11. Ziegler JL, Beckstead JA, Voberding PA, et al: Non-Hodgkin’s lymphoma in 90 homosexual men. 
Relation to generalized lymphadenopathy and the acquired immunodeficiency syndrome. N Engl J 
Med 311:565-70, 1984. 
12. Knowles DM, Chamulak GA, Subar M, et al: Lymphoid neoplasia of the acquired immunodeficiency 
syndrome (AIDS). The New York University Medical Center experience with 105 patients (1981- 
1986). Ann Intern Med 108:744-53, 1988. 
13. Appelbaum FR, Sullivan K, Buckner CD, et al: Treatment of malignant lymphoma in 100 patients 
with chemotherapy, total body irradiation, and marrow transplantation. J Clin Oncol 5:1340-1347, 
1987. 
14. Holland HK, Saral R, Rossi JJ, et al: Allogeneic bone marrow transplantation, zidovudine, and 
human immunodeficiency virus type 1 (HIV-1) infection. Ann Intern Med 111:973-981, 1989. 
[630] 
Recombinant DNA Research, Volume 15 
